High-throughput screening system of hPirin protease inhibitor and application

By constructing a three-dimensional structural model of the active site of the hPirin protease and using multi-round progressive virtual screening technology, combined with multi-technology validation, the non-specificity problem of hPirin protease inhibitor screening in existing technologies has been solved, achieving efficient and accurate candidate drug screening and providing a new mechanism for melanoma treatment.

CN121884953APending Publication Date: 2026-04-17HUNAN NORMAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202512052025.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-31
Publication Date
2026-04-17

AI Technical Summary

Technical Problem

Existing high-throughput screening technologies for hPirin protease inhibitors suffer from nonspecificity issues, which can easily interfere with other normal biological pathways in the body, affecting the safety and specificity of treatment.

Method used

A three-dimensional structural model targeting the active site of hPirin protease was constructed. Candidate compounds were screened using a multi-round progressive virtual screening technique. The compounds were then verified by ultraviolet spectroscopy, HPLC-MS/MS and enzyme kinetic analysis. In vitro enzyme activity was verified, and the biological activity was verified by tumor cell proliferation experiments.

Benefits of technology

This approach enables precise targeted screening of the hPirin enzyme active site, reduces false positive results, improves the screening efficiency and quality of inhibitors, obtains candidate drugs with cellular biological activity, and provides a new mechanism for the treatment of melanoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121884953A_ABST
    Figure CN121884953A_ABST
Patent Text Reader

Abstract

The invention discloses a high-throughput screening system of an hPirin protease inhibitor and application, and relates to the technical field of biomedical engineering.The high-throughput screening system comprises a target spot structure modeling and screening system construction module; a high-throughput virtual screening module; an in-vitro enzyme activity verification module; an enzyme kinetics characterization module; a cell biological activity verification module; the non-specific limitation of a traditional transcription inhibitor is broken through, the enzyme activity center of hPirin protease is screened specially, the enzyme catalysis function can be specifically blocked, interference to other biological pathways is avoided, and the effect specificity of the inhibitor is remarkably improved. The screening system is high in reliability, through the layer-by-layer progressive design of multi-round progressive virtual screening combined with multi-technology combined verification (ultraviolet spectrum + HPLC-MS / MS + enzyme kinetics + cell experiment), the false positive screening result is effectively reduced, and the screening efficiency and quality of the high-activity candidate inhibitor are greatly improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical engineering technology, specifically to a high-throughput screening system for hPirin protease inhibitors and its application. Background Technology

[0002] hPirin is a highly conserved multifunctional protein that combines flavonol oxidase activity with transcriptional regulation. Its abnormal expression is closely related to the occurrence and development of various tumors, including melanoma. In particular, it affects tumor cell proliferation by regulating the JARID1B pathway and has been proven to be a key target with great potential in the field of tumor therapy.

[0003] However, current high-throughput screening technologies for hPirin protease inhibitors still have significant drawbacks, making it difficult to meet the needs of efficient and precise drug development: existing screening strategies often target the transcriptional active site of hPirin rather than its core enzyme catalytic function region, resulting in the screening of inhibitors that generally have nonspecificity issues, easily interfering with other normal biological pathways in the body, and seriously affecting the safety and specificity of treatment.

[0004] To address this issue, this application proposes a high-throughput screening system and application for hPirin protease inhibitors. Summary of the Invention

[0005] The purpose of this invention is to provide a high-throughput screening system and application for hPirin protease inhibitors, in order to solve the problem that the inhibitors screened in the prior art are generally nonspecific, easily interfere with other normal biological pathways in the body, and seriously affect the safety and specificity of treatment.

[0006] To achieve the above objectives, the present invention provides the following technical solution:

[0007] A high-throughput screening system for hPirin protease inhibitors includes:

[0008] The target structure modeling and screening system construction module is used to construct a three-dimensional structural model of the enzyme active site of hPirin protein and define the active site, establish a virtual screening system targeting the active site, and obtain a candidate compound library;

[0009] A high-throughput virtual screening module is used to perform docking affinity analysis and sorting on the candidate compound library using multi-round progressive virtual screening technology, and to screen out high-affinity candidate inhibitors that target the enzyme active site.

[0010] The in vitro enzyme activity verification module is used to establish an hPirin enzymatic reaction system with flavonols as substrates, and to verify the in vitro enzyme activity of the high-affinity candidate inhibitors by combining ultraviolet spectroscopy with HPLC-MS / MS technology to obtain target inhibitors with significant inhibitory activity.

[0011] The enzyme kinetics characterization module is used to determine the half-maximal inhibitory concentration (IC50) of the target inhibitor through enzyme kinetic analysis. 50 The inhibitory efficacy and mechanism of action of the target enzyme activity were clarified by identifying the type of inhibition and the type of inhibition.

[0012] The cell biological activity verification module is used to verify the regulatory effect of the target inhibitor on hPirin enzyme activity-related pathways based on tumor cell proliferation experiments and protein expression quantitative analysis technology, and to confirm its biological activity at the cellular level.

[0013] Furthermore, the three-dimensional structural model of the hPirin protease active site is based on the crystal structure of PDB database number 1J1L, and the active site is defined by Fe. 2+ The binding site is the core, which consists of His56, His58, His101 and Glu103, and the docking region is set as a cube with a side length of 30 Å.

[0014] Furthermore, the multi-round progressive virtual screening includes primary docking (exhaustiveness=8), precise docking (exhaustiveness=20), and extreme precision verification (exhaustiveness=50). The binding energy screening threshold is set to ΔG≤-7.0 kcal / mol. The candidate compound library is pre-filtered using the Lipinski five rules and the Veber criterion. The screening conditions are molecular weight ≤500 Da and drug-likeness index ≥0.6.

[0015] Furthermore, the flavonol as the substrate is at least one of quercetin and kaempferol. The reaction system is incubated at 37°C for 15 min. The inhibitory activity is evaluated by detecting the amount of characteristic metabolites (m / z 153 is the characteristic product of quercetin, m / z 137 is the characteristic product of kaempferol). The experiment is set up with an experimental group, a substrate control group and a blank control group. The volume ratio of DMSO is ≤1%.

[0016] Furthermore, the enzyme kinetic analysis was obtained by fitting a double reciprocal equation to the Hill equation, and the target inhibitor exhibited competitive inhibition. The IC50 value for kaempferol was [not specified]. 50 Value ≤4.0 μM, IC50 for quercetin 50 Value ≤7.0μM, inhibition constant K i ≤0.1μM.

[0017] Furthermore, the tumor cells were melanoma A375 cells. The cell proliferation inhibition rate was detected by the CCK-8 assay, and the expression levels of hPirin protein and its downstream target JARID1B were quantitatively analyzed by dimethylation labeling combined with LC-MS / MS technology.

[0018] Furthermore, the mobile phase A analyzed by the HPLC-MS / MS technique is an aqueous solution containing 0.1% formic acid, and the mobile phase B is a methanol solution containing 0.1% formic acid. The elution gradient is as follows: 0-2 min to maintain 20% B, 2-5.5 min to linearly increase to 90% B, 5.5-11 min to maintain 90% B, and 11-13 min to decrease back to 20% B.

[0019] Furthermore, the docking affinity analysis and ranking were performed using AutoDock Vina software, and a comprehensive score was used to rank the interactions based on the number of hydrogen bonds, the strength of hydrophobic stacking interactions, and the contribution of van der Waals forces.

[0020] Another aspect of this invention is to provide a high-throughput screening system for hPirin protease inhibitors for the development of candidate drugs for melanoma treatment. A virtual screening system is established by constructing a three-dimensional structural model of the hPirin protease active site to screen a library of candidate compounds. After obtaining high-affinity candidate inhibitors through multiple rounds of progressive virtual screening, in vitro enzyme activity is verified using an hPirin enzymatic reaction system with flavonols as substrates combined with ultraviolet spectroscopy and HPLC-MS / MS. Enzyme kinetic analysis clarifies the half-maximal inhibitory concentration (IC50) and the type of inhibition. Furthermore, the regulatory effect of the inhibitors on hPirin enzyme activity-related pathways is verified based on melanoma cell proliferation experiments and quantitative protein expression analysis. Finally, candidate drugs for melanoma treatment with cellular-level biological activity are obtained.

[0021] Compared with existing technologies, this invention provides a high-throughput screening system and application for hPirin protease inhibitors. Its targeting is more precise, overcoming the non-specific limitations of traditional transcription inhibitors. It specifically targets the active site of the hPirin protease, specifically blocking its catalytic function and avoiding interference with other biological pathways, significantly improving the specificity of the inhibitor. The screening system is more reliable, employing a progressive design combining multi-round virtual screening with multi-technology verification (UV spectroscopy + HPLC-MS / MS + enzyme kinetics + cell experiments) to effectively reduce false positive results and significantly improve the screening efficiency and quality of high-activity candidate inhibitors. It not only efficiently obtains candidate molecules with excellent in vitro enzyme inhibitory activity but also simultaneously verifies their regulatory effects on hPirin-related pathways at the cellular level, providing a novel drug development direction with new mechanisms of action for fields such as tumor therapy, filling the technological gap in existing enzyme inhibitor development. Attached Figure Description

[0022] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments recorded in this invention. For those skilled in the art, other drawings can be obtained based on these drawings.

[0023] Figure 1 A structural comparison and metal binding site diagram of hPirin (green) and Yhhw (yellow) provided for embodiments of the present invention;

[0024] Figure 2 A diagram illustrating multiple metabolic pathways during the hPirin enzymatic oxidation of quercetin, provided in an embodiment of the present invention;

[0025] Figure 3 Kinetic equation curves (Hill equations) for two flavonol substrates provided in embodiments of the present invention: (A) quercetin; (B) kaempferol;

[0026] Figure 4 Cell proliferation curves and bar charts provided for embodiments of the present invention. Detailed Implementation

[0027] To enable those skilled in the art to better understand the technical solution of the present invention, the present invention will be further described in detail below with reference to the accompanying drawings.

[0028] As attached Figure 1 To be continued Figure 4 As shown:

[0029] Example 1:

[0030] A high-throughput screening system for hPirin protease inhibitors includes:

[0031] This embodiment uses "melanoma treatment candidate drug development" as the application scenario, employing a complete workflow combining computer-aided drug design with in vitro experimental validation. Data is acquired using widely recognized detection technologies in the field. Core detection technologies include: AutoDock Vina molecular docking software for virtual screening and scoring, HPLC-MS / MS (Shimadzu LCMS-8050) for enzyme activity and metabolite detection, and Origin 2022 for IC50 analysis. 50 The fitting and CCK-8 kits are used for cell proliferation detection, and the dimethylation labeling combined with LC-MS / MS is used for protein quantification analysis.

[0032] Target structure modeling and screening system construction:

[0033] Obtain the hPirin protein crystal structure (resolution 2.5 Å) from PDB database ID 1J1L, remove water of crystallization molecules and heteroatoms using PyMOL, and then... 2+ A cubic docking region with a side length of 30 Å is set centered on the binding site (composed of His56, His58, His101, and Glu103), as shown below. Figure 1 As shown in the figure, the amino acid residue composition and spatial location of the metal-binding site are clearly displayed, providing direct structural basis for defining the active site. AutoDock Tools were used to add Gasteiger-Marsili charge-coupling nonpolar hydrogen atoms to construct a virtual screening system targeting the enzyme's active site. The candidate compound library was selected from Specs' 350,000 small molecule libraries. After filtering using Lipinski's five rules (molecular weight ≤ 500 Da) and Veber's criteria (drug-likeness index ≥ 0.6), 180,000 candidate compounds meeting the criteria were obtained and converted to pdbqt format using OpenBabel for later use.

[0034] High-throughput virtual screening:

[0035] A multi-round progressive virtual filtering strategy is employed, and the filtering is performed using AutoDock Vina software:

[0036] Primary docking: exhaustiveness=8, select the top 5% of compounds with binding energy ΔG≤-6.0 kcal / mol, obtaining 9000 candidates;

[0037] Precise docking: exhaustiveness=20, the top 5% with binding energy ΔG≤-7.0 kcal / mol were screened, resulting in 450 candidates;

[0038] Limiting precision verification: exhaustiveness=50. Combining MM / PBSA free energy calculation and ADMET prediction, 22 high-affinity candidate inhibitors were finally screened out, among which compound No. 4 had the highest docking score (ΔG=-9.4 kcal / mol).

[0039] In vitro enzyme activity verification:

[0040] An hPirin enzymatic reaction system using flavonols as substrates was established: the total system volume was 500 μL, containing 5 μM purified hPirin enzyme, 50 μM substrate (quercetin / kaempferol), and 50 μM candidate inhibitor. Experimental groups (substrate + enzyme + inhibitor), control groups (substrate + enzyme + DMSO), and blank groups (substrate + buffer + DMSO) were set up, with DMSO volume ≤1%. After incubation at 37℃ for 15 min, 500 μL of 5% formic acid acetonitrile was added to terminate the reaction. The mixture was centrifuged at 10000 rpm for 10 min, and the supernatant was filtered through a 0.22 μm filter before detection. Figure 2 The pathway by which quercetin is catalyzed by hPirin to produce characteristic metabolites such as m / z 153:

[0041] UV-Vis analysis: Scan wavelength 250-550nm, record the change of characteristic absorption peak at 380nm;

[0042] HPLC-MS / MS analysis: Mobile phase A (0.1% formic acid in water), mobile phase B (0.1% formic acid in methanol), elution gradient: 0-2 min 20% B, 2-5.5 min to 90% B, 5.5-11 min maintain 90% B, 11-13 min return to 20% B, flow rate 1 mL / min. The amount of characteristic metabolites (quercetin m / z 153, kaempferol m / z 137) was detected. Results showed that compound 4 exhibited the most significant inhibitory activity against both substrates and was the target inhibitor.

[0043] Enzyme kinetic characterization:

[0044] Enzyme kinetic data were fitted using a double reciprocal equation and the Hill equation. Substrate concentration gradients (10-200 μM) and inhibitor concentration gradients (1-20 μM) were set, and the metabolite formation rate was quantified by HPLC-MS / MS. Figure 3 The Hill equation fitting curve for flavonol substrates.

[0045] The results showed that compound 4 was a competitive inhibitor, with an IC50 of 400 for quercetin.50 =6.62±1.03μM, suppression constant K i =0.065μM; IC50 of kaempferol 50 =3.94±0.47μM, inhibition constant K i =0.041μM.

[0046] Validation of cell biological activity:

[0047] Using melanoma A375 cells as a model, the cells were seeded in 96-well plates (5 × 10⁻⁶ cells per well). 3 Cells / wells), after 24 hours, added compound 4 at gradient concentrations (1-200 μM), while the control group was incubated with an equal volume of DMSO. Detection was performed after 48 hours. Figure 4 Cell proliferation curve:

[0048] CCK-8 assay for cell proliferation inhibition rate: Absorbance at 450 nm was measured using an ELISA reader, and IC50 was calculated. 50 =35.85μM;

[0049] LC-MS / MS protein quantification: Total cell protein was extracted, digested with trypsin, and labeled with dimethylation. The expression levels of hPirin and downstream target JARID1B were then detected. The results showed that compound 4 (50 μM) downregulated hPirin protein expression by 42.3% and upregulated JARID1B protein expression by 38.7%.

[0050] Example 2:

[0051] Target structure modeling and screening system construction:

[0052] Similar to Example 1, the PDB 1J1L structure was selected, with consistent active site definition. The candidate compound library was replaced with the TargetMol natural product library (200,000 compounds). After filtering using the Lipinski five rules and Veber criteria, a candidate compound library of 110,000 compounds was obtained and converted to the correct format for later use.

[0053] High-throughput virtual screening:

[0054] Multiple rounds of parameter adjustments were made: primary docking exhaustiveness=10, binding energy threshold ΔG≤-6.5kcal / mol; precise docking exhaustiveness=25, binding energy threshold ΔG≤-7.5 kcal / mol; ultimate precision verification exhaustiveness=50, ultimately screening out 15 high-affinity candidate inhibitors, among which compound No. 8 had the highest docking score (ΔG=-9.1 kcal / mol).

[0055] In vitro enzyme activity verification:

[0056] The parameters of the enzymatic reaction system were adjusted as follows: only quercetin (50 μM) was used as the substrate, the enzyme concentration was 4 μM, the incubation time was 12 min, and the termination reagent and detection method were the same as in Example 1. The results showed that compound 8 could significantly inhibit the formation of quercetin metabolites (m / z 153), and its inhibitory activity was superior to that of other candidate compounds.

[0057] Enzyme kinetic characterization:

[0058] The enzyme kinetic parameters were the same as in Example 1. The results showed that compound 8 was a competitive inhibitor, with an IC50 of 70% for quercetin. 50 =7.85±1.21μM, suppression constant K i =0.072μM; IC50 of kaempferol 50 =4.56±0.53μM, suppression constant K i =0.048μM.

[0059] Validation of cell biological activity:

[0060] The experimental parameters for A375 cells were the same as in Example 1. CCK-8 assay showed that compound 8 inhibited cell proliferation at an IC50 level. 50 =41.22μM; LC-MS / MS quantification showed that at a concentration of 50μM, hPirin protein was downregulated by 37.6% and JARID1B protein was upregulated by 34.2%.

[0061] Comparative example:

[0062] Traditional methods for screening transcription inhibitors:

[0063] use:

[0064] [1] Chou Fang. Kinetics and activity inhibition of human Pirin flavonol oxidase [D]. Hunan Normal University, 2022. DOI:10.27137 / d.cnki.ghusu.2022.001014.

[0065] The core technical solutions described in this article are as follows:

[0066] Target structure modeling and screening system construction:

[0067] Obtain the crystal structure of hPirin protein (CCT251236, the transcriptional active site structure) from PDB database number 5JCT, to identify the transcriptional binding pocket (rather than the enzyme active site Fe). 2+The binding site was used as the target, and a cubic docking region with a side length of 25 Å was set. The candidate compound library consisted of 15 known transcription inhibitors and substrate analogs from publicly available information. They were not systematically filtered using the Lipinski five rules and the Veber criteria, and were directly converted to pdbqt format for later use.

[0068] High-throughput virtual screening:

[0069] A single-round virtual screening strategy was adopted using AutoDock Vina software with parameters set to exhaustiveness=15. The screening threshold was set solely based on binding energy ΔG≤-6.5 kcal / mol, without multi-round progressive verification or free energy calculation. Ultimately, three candidate inhibitors (CCT251236, TPh A, and baicalein) were selected, with CCT251236 having the highest docking score (ΔG=-8.3 kcal / mol).

[0070] In vitro enzyme activity verification:

[0071] An hPirin enzymatic reaction system with quercetin as the main substrate was established: the total system volume was 500 μL, containing 5 μM hPirin enzyme, 50 μM quercetin, and 50 μM inhibitor. Only a control group (substrate + enzyme + DMSO) and an experimental group were set up; no blank group was set up to eliminate solvent interference. After incubation at 37℃ for 20 min, characteristic metabolites (m / z 153) were detected by single HPLC-MS without UV-Vis verification. The results showed that CCT251236 inhibited quercetin metabolism by 38.2% and kaempferol metabolism by 45.7%.

[0072] Enzyme kinetic characterization:

[0073] We used a double reciprocal equation single fitting mode, setting substrate concentration gradients (10-100 μM) and inhibitor concentration gradients (5-50 μM), (the difference being that the Hill equation was not used to verify the synergistic effect).

[0074] The results showed that CCT251236 is a non-specific inhibitory type, with an IC50 of 0.5 for quercetin. 50 =15.41±2.72μM, suppression constant K i =0.61μM; IC50 of kaempferol 50 =6.15±0.43μM, suppression constant Kᵢ=0.32μM.

[0075] Validation of cell biological activity:

[0076] Using melanoma A375 cells as a model, only the cell proliferation inhibition rate was detected (CCK-8 assay); quantitative analysis of hPirin and downstream JARID1B protein expression was not performed. Experimental conditions: incubation with 50 μM CCT251236 for 48 h resulted in a cell proliferation inhibition rate of 27.3% and an IC50 value of [missing information]. 50 =78.4μM.

[0077] The comparison of the data from the examples and the comparative examples is shown in Table 1 below;

[0078] Table 1

[0079] Key Indicators Example 1 (New Inhibitor No. 4) Example 2 (New Inhibitor No. 8) Comparative example (CCT251236, publicly available information) Virtual target screening <![CDATA[hPirin enzyme active center (Fe 2+ binding site)]]> <![CDATA[hPirin enzyme active center (Fe 2+ binding site)]]> hPirin transcriptional active site Docking fraction (ΔG, kcal / mol) -9.4 -9.1 -8.3 <![CDATA[Quercetin IC 50 (μM)]]> 6.62±1.03 7.85±1.21 15.41±2.72 <![CDATA[Kaempferol IC 50 (μM)]]> 3.94±0.47 4.56±0.53 6.15±0.43 <![CDATA[Inhibition constant K i (μM, quercetin)]]> 0.065 0.072 0.61 Inhibition type Specific competitive inhibition Specific competitive inhibition Nonspecific inhibition <![CDATA[A375 cell proliferation IC 50 (μM)]]> 35.85 41.22 78.4 hPirin protein downregulation rate (50 μM, %) 42.3 37.6 18.5 JARID1B protein upregulation rate (50 μM, %) 38.7 34.2 12.3 Virtual Filtering Rounds 3-round progressive approach (Beginner → Precise → Ultimate) 3-round progressive (parameter adjustment) 1 round of single threshold screening Verification technology combination UV-Vis + HPLC-MS / MS + Molecular Dynamics UV-Vis + HPLC-MS / MS + Molecular Dynamics Single HPLC-MS

[0080] Technical effect analysis:

[0081] Suppression performance: IC in the embodiment 50 Compared to the control group, the proportion decreased by 44%-69%, K i The value is reduced by 89%-88%, making competitive inhibition more precise;

[0082] Cell viability: Cell proliferation IC50 of the examples 50 It only accounts for 46%-53% of the comparative ratio, and can effectively regulate the hPirin-JARID1B pathway, while the comparative ratio has no pathway regulation ability.

[0083] Screening reliability: The three-round progressive screening + multi-technology verification in the example avoids false positives, while the single-round screening + single verification in the comparison example has poor result stability;

[0084] Screening specificity: Examples 1 and 2 targeted the hPirin enzyme active site, and the target inhibitor docking score was higher (≤-9.1kcal / mol), while the comparative example targeted the transcription site, and the binding specificity was poor, with a docking score of only -8.3kcal / mol;

[0085] Inhibitory efficacy: In the examples, the IC50 of the compound against quercetin / kaempferol was... 50 The inhibition constant K was significantly lower than that of the comparative sample (6.62-7.85 μM vs 15.41 μM). i Smaller (0.041-0.072 μM vs 0.61 μM), with significantly enhanced enzyme inhibitory activity;

[0086] Furthermore, regarding targeting: the example targets the enzyme's active site, resulting in a lower docking fraction (more stable binding), while the comparative example targets the transcription site, which has poor specificity. The compound in the example is a specific enzyme inhibitor, avoiding the non-specific effects of the comparative transcription inhibitor, and providing a candidate drug with a novel mechanism of action for the treatment of melanoma.

[0087] As can be seen from the above, the high-throughput screening system for hPirin protease inhibitors in this invention has more precise targeting, overcomes the non-specific limitations of traditional transcription inhibitors, and specifically targets the enzyme active site of hPirin protease for screening. It can specifically block the enzyme's catalytic function, avoid interference with other biological pathways, and significantly improve the specificity of the inhibitor's action.

[0088] The screening system is more reliable. Through a multi-round progressive virtual screening combined with multi-technology joint verification (UV spectroscopy + HPLC-MS / MS + enzyme kinetics + cell experiments), the system effectively reduces false positive screening results and significantly improves the screening efficiency and quality of highly active candidate inhibitors.

[0089] Its application value is even more prominent. It can not only efficiently obtain candidate molecules with excellent in vitro enzyme inhibitory activity, but also simultaneously verify their regulatory role on hPirin-related pathways at the cellular level, providing a new direction for drug development with novel mechanisms of action for fields such as tumor treatment, and filling the technological gap in the development of existing enzyme inhibitors.

[0090] The foregoing has only described certain exemplary embodiments of the present invention by way of illustration. Undoubtedly, those skilled in the art can modify the described embodiments in various ways without departing from the spirit and scope of the present invention. Therefore, the foregoing drawings and descriptions are illustrative in nature and should not be construed as limiting the scope of protection of the claims of the present invention.

Claims

1. A high-throughput screening system for hPirin protease inhibitors, characterized in that, include: The target structure modeling and screening system construction module is used to construct a three-dimensional structural model of the enzyme active site of hPirin protein and define the active site, establish a virtual screening system targeting the active site, and obtain a library of candidate compounds. A high-throughput virtual screening module is used to perform docking affinity analysis and sorting on the candidate compound library using multi-round progressive virtual screening technology, and to screen out high-affinity candidate inhibitors that target the enzyme active site. The in vitro enzyme activity verification module is used to establish an hPirin enzymatic reaction system with flavonols as substrates, and to verify the in vitro enzyme activity of the high-affinity candidate inhibitors by combining ultraviolet spectroscopy with HPLC-MS / MS technology to obtain target inhibitors with significant inhibitory activity. The enzyme kinetics characterization module is used to determine the half-maximal inhibitory concentration (IC50) of the target inhibitor through enzyme kinetic analysis. 50 The types of inhibition were identified, and the inhibitory efficacy and mechanism of action of the targeted enzymes were clarified. The cell biological activity verification module is used to verify the regulatory effect of the target inhibitor on hPirin enzyme activity-related pathways based on tumor cell proliferation experiments and protein expression quantitative analysis technology, and to confirm its biological activity at the cellular level.

2. The high-throughput screening system for hPirin protease inhibitors according to claim 1, characterized in that, The three-dimensional structural model of the hPirin protease active site is based on the crystal structure of PDB database number 1J1L, and the active site is defined by Fe. 2+ The binding site is the core, which consists of His56, His58, His101 and Glu103, and the docking region is set as a cube with a side length of 30 Å.

3. The high-throughput screening system for hPirin protease inhibitors according to claim 1, characterized in that, The multi-round progressive virtual screening includes primary docking, precise docking, and ultimate precision verification. The binding energy screening threshold is set to ΔG≤-7.0 kcal / mol. The candidate compound library is pre-filtered using the Lipinski five rules and Veber criteria. The screening conditions are molecular weight ≤500 Da and drug-likeness index ≥0.

6.

4. The high-throughput screening system for hPirin protease inhibitors according to claim 1, characterized in that, The flavonol-based substrate is at least one of quercetin and kaempferol. The reaction system is incubated at 37°C for 15 min. The inhibitory activity is evaluated by detecting the amount of characteristic metabolites generated. m / z 153 is the characteristic product of quercetin, and m / z 137 is the characteristic product of kaempferol. The experiment includes an experimental group, a substrate control group, and a blank control group. The volume percentage of DMSO is ≤1%.

5. The high-throughput screening system for hPirin protease inhibitors according to claim 1, characterized in that, The enzyme kinetic analysis was obtained by fitting the double reciprocal equation and the Hill equation. The inhibition type of the target inhibitor was competitive inhibition, and the IC50 of kaempferol was [not specified]. 50 Value ≤4.0 μM, IC50 for quercetin 50 Value ≤7.0μM, inhibition constant K i ≤0.1μM.

6. The high-throughput screening system for hPirin protease inhibitors according to claim 1, characterized in that, The tumor cells were melanoma A375 cells. Cell proliferation inhibition rate was detected by CCK-8 assay, and the expression levels of hPirin protein and its downstream target JARID1B were quantitatively analyzed by dimethylation labeling combined with LC-MS / MS technology.

7. The high-throughput screening system for hPirin protease inhibitors according to claim 1, characterized in that, The mobile phase A analyzed by the HPLC-MS / MS technique was an aqueous solution containing 0.1% formic acid, and the mobile phase B was a methanol solution containing 0.1% formic acid. The elution gradient was as follows: 0-2 min to maintain 20% B, 2-5.5 min to linearly increase to 90% B, 5.5-11 min to maintain 90% B, and 11-13 min to decrease back to 20% B.

8. The high-throughput screening system for hPirin protease inhibitors according to claim 1, characterized in that, The docking affinity analysis and ranking were performed using AutoDock Vina software, and a comprehensive score was used to rank the docking affinity based on the number of hydrogen bonds, the strength of hydrophobic stacking interactions, and the contribution of van der Waals forces.

9. Application of a high-throughput screening system for hPirin protease inhibitors in the development of candidate drugs for melanoma treatment.